AIMS: The aim of this work was to assess the feasibility of using dynamic contrast enhanced (DCE) MRI of @entity236 , to compare it with conventional marrow @entity4 scoring systems, and to determine the effects of anti- @entity5 @entity39 factor ( @entity310 therapy. METHODS: The wrist and metacarpophalangeal (MCP) joints of 25 @entity1 with @entity309 were studied. A total of 14 were imaged before and 1-2 weeks after anti- @entity310 therapy. T2-weighted fat-suppressed images were collected. A dynamic series of 24 3D spoiled gradient-echo images were acquired before, during and after the intravenous administration of @entity2287 -based contrast medium. @entity4 was scored using the conventional @entity309 MRI Scoring (RAMRIS) system from T2-weighted images. The relative enhancement rate (RER) was calculated using the dynamic series from oedematous bone, bone adjacent to @entity4 and from an uninvolved bone. RESULTS: A total of 56% of @entity1 showed @entity236 . The RER was significantly increased in and adjacent to areas of marrow @entity4 . There was a significant reduction in the RER after treatment, but not in the RAMRIS score. CONCLUSIONS: Dynamic contrast enhanced MRI of @entity236 yields additional information to RAMRIS scoring and may be a more sensitive marker of inflammatory activity and response to treatment.

Dynamic contrast enhanced MRI of XXXX in @entity309 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity4 :: ('MESH:D004487', 'Disease') :: ['Oedema', 'oedema'] @entity310 :: ('7124', 'Gene') :: ['TNFalpha', 'TNF)alpha'] @entity236 :: ('MESH:D001855', 'Disease') :: ['bone marrow oedema'] @entity2287 :: ('MESH:D005682', 'Chemical') :: ['gadolinium'] @entity309 :: ('MESH:D001172', 'Disease') :: ['Rheumatoid Arthritis', 'rheumatoid arthritis']
@entity236 :: (MESH:D001855,Disease) :: ['bone marrow oedema']
